GSK-LSD1
CAT:
HY-100546
HY-100546
804-HY-100546
Size:
1 Each
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


GSK-LSD1
Description:
GSK-LSD1, a chemical probe, is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3].UNSPSC:
12352005Hazard Statement:
H302-H315-H319-H335Target:
Histone DemethylaseType:
Reference compoundRelated Pathways:
EpigeneticsApplications:
Metabolism-protein/nucleotide metabolismField of Research:
Cancer; Infection; Metabolic DiseaseAssay Protocol:
https://www.medchemexpress.com/gsk-lsd1.htmlSolubility:
10 mM in DMSOSmiles:
C1(N[C@H]2[C@H](C3=CC=CC=C3)C2)CCNCC1Molecular Formula:
C14H20N2Molecular Weight:
216.32Precautions:
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501References & Citations:
[1]Ramms B, et al. Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. Diabetes. 2022 Dec 1;71 (12) :2513-2529.|[2]Alsaqer SF, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8 (43) :73372-73386.|[3]Hong KS, et al. GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro. Signal Transduct Target Ther. 2020 Nov 17;5 (1) :267.Shipping Conditions:
Room temperatureScientific Category:
Reference compound1Clinical Information:
No Development ReportedCitation 01:
Res Sq. 2025 Apr 01.|Adv Mater. 2021 May;33 (18) :e2100949.|Bioorg Chem. 2024 Jul 1:150:107603.|bioRxiv. 2024 Aug 19:2024.08.17.607802.|Clin Exp Med. 2025 Nov 25;26 (1) :33.|Cytokine. 2022 Mar:151:155789.|Nat Commun. 2021 Dec 8;12 (1) :7142.|Nat Commun. 2025 Feb 1;16 (1) :1241.|Nat Commun. 2025 Jan 2;16 (1) :212.|Nature. 2025 Jun;642 (8067) :508-518.|Patent. US20180263995A1.|Signal Transduct Target Ther. 2022 Apr 13;7 (1) :102.CAS Number:
[1431368-48-7]
